Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors

NCT05718557 is registered in ClinicalTrials.gov with Pyxis Oncology, Inc as lead sponsor.

NCT NCT05718557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05718557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors
Lead sponsor
Pyxis Oncology, Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 23, 2023
Completion date
May 31, 2026
Enrollment
47 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor